OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
38393056

DT&CRO Co Ltd

Healthcare Facilities & ServicesVerified

DT&CRO's capital structure shows a debt-to-equity ratio of 1.44, indicating a leveraged position relative to equity. The company's liquidity is constrained, with a current ratio of 0.52, suggesting short-term obligations may exceed current assets. Free cash flow is negative at -8.4 billion KRW, and operating cash flow is also negative at -2.3 billion KRW, reflecting ongoing cash outflows from operations. Profitability metrics are negative, with a return on equity of -11.07% and a return on assets of -3.07%, both significantly below industry norms for contract research organizations. The company reported a net loss of 2.8 billion KRW and an operating loss of 5.7 billion KRW, indicating a challenging operating environment. Revenue is concentrated in a single business segment focused on contract research, with no disclosed geographic diversification in the financial snapshot. This lack of segment or geographic diversification increases exposure to sector-specific risks. Growth trajectory is uncertain, with no forward-looking revenue guidance provided in the financial snapshot. Historical performance shows declining profitability, with a net loss in the latest reporting period. The company's capital expenditure of -11.9 billion KRW suggests investment in infrastructure, but this has not yet translated into positive cash flow or profitability. Risk factors include liquidity constraints and a leveraged capital structure. The company has a medium liquidity risk rating, and its net cash position is negative after subtracting total debt. Dilution risk is low, with no near-term pressure from share issuance or convertible debt. Recent filings and transcripts are not included in the input data, so no specific events can be cited for the latest period.

30-day price · 383930-535.00 (-15.7%)
Low$2260.00High$3865.00Close$2870.00As of21 May, 00:00 UTC
Profile
CompanyDT&CRO Co Ltd
Ticker383930.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. DT&CRO Co Ltd provides non-clinical and clinical trial services in pharmaceuticals, medical devices, food, chemicals, and cosmetics.

Classification. DT&CRO is classified in the Healthcare Facilities & Services industry under the Healthcare Services & Equipment business sector with 92% confidence.

DT&CRO's capital structure shows a debt-to-equity ratio of 1.44, indicating a leveraged position relative to equity. The company's liquidity is constrained, with a current ratio of 0.52, suggesting short-term obligations may exceed current assets. Free cash flow is negative at -8.4 billion KRW, and operating cash flow is also negative at -2.3 billion KRW, reflecting ongoing cash outflows from operations. Profitability metrics are negative, with a return on equity of -11.07% and a return on assets of -3.07%, both significantly below industry norms for contract research organizations. The company reported a net loss of 2.8 billion KRW and an operating loss of 5.7 billion KRW, indicating a challenging operating environment. Revenue is concentrated in a single business segment focused on contract research, with no disclosed geographic diversification in the financial snapshot. This lack of segment or geographic diversification increases exposure to sector-specific risks. Growth trajectory is uncertain, with no forward-looking revenue guidance provided in the financial snapshot. Historical performance shows declining profitability, with a net loss in the latest reporting period. The company's capital expenditure of -11.9 billion KRW suggests investment in infrastructure, but this has not yet translated into positive cash flow or profitability. Risk factors include liquidity constraints and a leveraged capital structure. The company has a medium liquidity risk rating, and its net cash position is negative after subtracting total debt. Dilution risk is low, with no near-term pressure from share issuance or convertible debt. Recent filings and transcripts are not included in the input data, so no specific events can be cited for the latest period.
Key takeaways
  • DT&CRO operates in a specialized healthcare services sector with high capital intensity.
  • The company is currently unprofitable, with negative returns on equity and assets.
  • Liquidity is a concern, with a current ratio below 1 and negative operating cash flow.
  • Growth is uncertain without clear revenue guidance or profitability improvement.
  • The business is concentrated in a single segment, increasing sector-specific risk.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$47.75B
Gross profit$2.61B
Operating income-$5.74B
Net income-$2.78B
R&D
SG&A
D&A
SBC
Operating cash flow-$2.26B
CapEx-$11.92B
Free cash flow-$8.40B
Total assets$90.38B
Total liabilities$65.29B
Total equity$25.09B
Cash & equivalents
Long-term debt$36.06B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$25.09B
Net cash-$36.06B
Current ratio0.5
Debt/Equity1.4
ROA-3.1%
ROE-11.1%
Cash conversion81.0%
CapEx/Revenue-25.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric383930Activity
Op margin-12.0%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin-5.8%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin5.5%19.7% medp25 19.7% · p75 39.8%bottom quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-25.0%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity144.0%71.3% medp25 19.0% · p75 91.7%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 12:21 UTC#b3372f80
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 14:59 UTCJob: 2abe9a6b